The *questions* readers arrive with

Can a doctor prescribe retatrutide?

Not in the United States, outside a clinical trial. A prescription is a clinician's authorization to dispense a drug that the FDA has approved for marketing. Retatrutide has not received FDA approval for any indication, and a New Drug Application has not yet been submitted. The earliest realistic NDA timeline is late 2026, contingent on TRIUMPH-1 and TRIUMPH-3 reading out ^[11][12]. Outside an authorized clinical trial operating under an Investigational New Drug exemption, there is no lawful pathway to dispense retatrutide for human use.

Is retatrutide available by prescription anywhere?

No major regulator — FDA, EMA, MHRA, PMDA, TGA, Health Canada — has approved retatrutide as of 2026. The only setting in which a participant can receive retatrutide is an authorized clinical trial, which is governed by the trial protocol and the sponsor's drug-supply chain, not by ordinary prescription dispensing. The current Phase 3 trials are listed on ClinicalTrials.gov; TRIUMPH-1 is NCT05929066 and TRIUMPH-3 is NCT05882045 ^[11][12].

When will retatrutide be FDA-approved?

Approval depends on the readouts from the Phase 3 TRIUMPH program. TRIUMPH-4 reported positive topline data in December 2025 in adults with obesity plus knee osteoarthritis ^[8]. TRIUMPH-1, the pivotal general-obesity trial, is expected to read out in 2026 ^[11]. TRIUMPH-3, the cardiovascular outcomes trial, will report later ^[12]. A New Drug Application filing is realistically late 2026; commercial availability, contingent on FDA review, is not anticipated before 2027 or 2028. Predictions tighter than that are speculation.

Why can't compounding pharmacies make retatrutide?

There are two compounding pathways in U.S. federal law: 503A (traditional pharmacy compounding) and 503B (registered outsourcing facilities). To compound from a bulk drug substance under either pathway, the substance must satisfy one of three tests — it must be the subject of an applicable USP or NF monograph, it must be a component of an FDA-approved drug, or it must appear on the relevant bulks list. Retatrutide satisfies none of those tests. It has also never appeared on the FDA drug shortage list, which closes the additional 503A shortage pathway that was used during the GLP-1 shortages of 2022–2024. On 9 September 2025 the FDA issued more than 40 warning letters, several of which explicitly named retatrutide as an investigational substance that 'cannot be used in compounding under federal law' ^[16][17]. A compounded retatrutide product distributed in the U.S. is, by FDA framing, an unapproved new drug.

How does retatrutide compare to tirzepatide and semaglutide?

Mechanistically, semaglutide is a GLP-1 mono-agonist, tirzepatide is a GLP-1/GIP dual agonist, and retatrutide is a GLP-1/GIP/GCG tri-agonist. The third arm — glucagon-receptor agonism — adds an energy-expenditure and hepatic-fat-oxidation contribution that the others lack.

Quantitatively, the Phase 2 retatrutide obesity trial reported -24.2% weight loss at 48 weeks on the 12 mg arm in adults without type 2 diabetes ^[1]. The published Phase 3 trials of tirzepatide (SURMOUNT-1) and semaglutide (STEP-1) reported maximum weight reductions in the high teens to low twenties at 68–72 weeks. Cross-trial comparisons are crude — different populations, different durations, different protocols — but the rough direction is that retatrutide's effect size is larger. Whether it is clinically meaningfully larger, and at what safety cost, is what TRIUMPH-1 and TRIUMPH-3 are designed to characterize.

What were the results of the Phase 2 retatrutide trial?

The Phase 2 obesity trial published in NEJM in 2023 randomized adults with obesity (BMI ≥30, or ≥27 with comorbidity) and without type 2 diabetes ^[1]. At 48 weeks the 12 mg arm reduced body weight by 24.2% versus 2.1% on placebo. The 24-week interim data showed dose-response across the 1, 4, 8, and 12 mg arms with no plateau ^[2]. The parallel Phase 2 trial in type 2 diabetes reported HbA1c reductions of about 2.0 percentage points and weight loss of about 16.9% at 24 weeks at the 12 mg dose ^[3]. A Phase 2a MASLD substudy reported an 86.0% reduction in liver fat at 48 weeks at the 12 mg dose ^[4].

What is the TRIUMPH program and when will results be available?

TRIUMPH is the Phase 3 development program for retatrutide — at least five trials across general obesity, type 2 diabetes, obesity with established cardiovascular disease, obesity with knee osteoarthritis, and obstructive sleep apnea. TRIUMPH-4 (knee OA) reported positive topline in December 2025 ^[8]. TRIUMPH-1 (general obesity, NCT05929066) is expected in 2026 ^[11]. TRIUMPH-3 (cardiovascular outcomes, NCT05882045) will report later ^[12]. Full publications typically follow topline announcements by several months.

How can someone join a retatrutide clinical trial?

Active and recruiting trials are listed on ClinicalTrials.gov. The TRIUMPH program entries include detailed eligibility criteria and the list of participating sites. Enrollment is handled by the individual trial sites, not by the sponsor directly. As trials complete enrollment, recruitment closes — by 2026 several TRIUMPH arms are likely already fully enrolled. This site does not maintain a real-time recruitment status; consult ClinicalTrials.gov ^[11][12].

What are the side effects of retatrutide?

The adverse-event profile reported across Phase 1 and Phase 2 is broadly consistent with the incretin class. Nausea, vomiting, and diarrhea are the most common events, concentrated in the first 16 weeks of titration. In the Phase 2 obesity trial, nausea was reported in 36% of participants on the 1 mg arm and 59% on the 12 mg arm; vomiting in 8% to 39% ^[9]. Treatment-discontinuation rates ranged from 6% to 16% across the dose cohorts. A dose-dependent transient rise in resting heart rate of roughly +6.7 bpm at the 12 mg dose at 24 weeks has been reported, drifting back toward baseline through weeks 36–48 ^[10]. Hepatic safety appears reassuring through 48 weeks ^[4], but long-term safety in broad populations will be characterized by the Phase 3 program.

Is retatrutide sold legally as a research chemical?

Vendors selling material labeled 'retatrutide' typically frame it as 'for research use only, Whatever the label says, the FDA's September 2025 enforcement made clear that distribution of retatrutide for human use — including via the 'research chemical' framing where the material is implicitly understood to be self-administered — constitutes introduction of an unapproved new drug into interstate commerce ^[16][17]. The identity, purity, sterility, and potency of material from non-sponsor sources are not independently verifiable; the trial-supplied material that produced the published efficacy and safety data is not the same supply chain.

Is retatrutide on the WADA prohibited list?

GLP-1, GIP, and glucagon receptor agonists are not categorically prohibited in sport. However, retatrutide is an investigational substance, and investigational substances generally fall under WADA's S0 category (Non-Approved Substances), which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Athletes subject to WADA testing should treat retatrutide as prohibited and should consult the current WADA Prohibited List.

Why does this site exist if it cannot help me get a script?

Because the search term 'retatrutide prescription' generates more confusion than any single article can usefully clear up. This site is an editorial brief that summarizes what the published research literature actually shows and what the regulatory framework actually permits, in plain English, with citations. It is not a clinic, not a pharmacy, not a vendor, and not a referral service. See /about for the editorial standards.